Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-3028 in mCRPC
NCT07285694Phase 2Active, not recruiting
- Sponsor
- Arsenal Biosciences, Inc.
- Start
- Jan 2026
- Primary completion
- May 2029
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of AB-3028 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Arsenal Biosciences, Inc.. Started Jan 2026; status: active, not recruiting.
02
Drugs
AB-3028
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07285694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07285694.